DePuy Synthes Q1 sales up 1.1%, spine drops 8.9% after Codman divestiture: 5 points

Written by Laura Dyrda | April 18, 2018 | Print  | Email

In the first quarter of 2017, Johnson & Johnson reported their orthopedics business, DePuy Synthes, had a slight 1.1 percent growth over the same period last year.

 

Here are five things to know.

1. The company's spine business sales had the largest decline, at 8.9 percent, reaching $804 million. Trauma sales were up 8.4 percent to $696 million. Hip sales grew 3.1 percent and knee sales dropped 2.8 percent to $363 million and $387 million, respectively.

2. Overall orthopedics sales hit $2.2 billion in the first quarter as the second largest sales group in the medical devices business line. The company's surgery line — which includes endocutters, biosurgery and energy — sales reached $2.4 billion with a 6.7 percent growth for the quarter.

3. Growth in hip sales was driven by leadership in the anterior approach and the ACTIS stem, offsetting flat U.S. sales. The company attributed spine losses to its Codman divestiture and knee losses to the competitive pressure in the U.S. as well as declines in the EMEA markets.

4. U.S. orthopedics sales overall were down 3.8 percent in the first quarter while international sales were up 2.9 percent. The U.S. sales hit $1.3 billion.

5. The company's knee business reported 7.3 percent sales drop in the U.S., but 4.6 percent growth in international markets.

More articles on orthopedic devices:
36 orthopedic & spine device companies to know | 2018
Stryker's spine division to drive Q1 sales: 5 insights
Medtronic, Spineology, Zimmer Biomet & more: 9 device company notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.